LeapFrog targets $100M India healthcare bet over two years
LeapFrog plans to invest $80M-$100M in India's healthcare over two years, targeting hospitals, specialty-care, and diagnostics as insurance penetration rises.
Alpha Score of 49 reflects weak overall profile with weak momentum, strong value, poor quality, moderate sentiment.
Global private equity firm LeapFrog Investments plans to invest $80 million to $100 million in India’s healthcare sector over the next two years, a top executive told Reuters. The firm is drawing on an $808 million fund and related co-investment vehicles that give it more than $1 billion to deploy across Asia and Africa.
Rising insurance coverage, greater use of diagnostics, and a shift toward preventive care in a country with high rates of chronic disease have pushed healthcare spending higher. India’s healthcare sector was valued at about $180 billion in 2023 and is expected to reach $320 billion by 2028, government data showed. The healthcare and pharmaceutical sector recorded 594 M&A and private equity deals worth over $30 billion between 2022 and 2024, according to data from advisory firm Grant Thornton Bharat and the Association of Healthcare Providers India.
KKR’s deal to acquire Medicover Hospital’s India business for 1.2 billion euros ($1.4 billion) is among the latest transactions.
LeapFrog is evaluating hospitals that serve patients outside major cities, Biju Mohandas, the firm’s global head and partner for healthcare, told Reuters. It is also targeting specialty-care providers in maternal and child health and ophthalmology, with oncology under consideration, he said. The firm is exploring an investment in an asset-light, single-specialty healthcare provider, though Mohandas declined to give details.
“Our investment thesis is centred on two realities, growing insurance penetration and significant disposable income with the ability to afford quality healthcare,” Mohandas said.
LeapFrog’s existing Indian investments include diagnostics provider Redcliffe Labs and digital health platform Healthify. The firm is also looking at opportunities in India’s pharmaceutical and medical equipment sectors, Mohandas said.
“We have already deployed a significant portion of the capital, including recent investments in the Philippines and Vietnam, but we see substantial deployment opportunities in India over the next couple of years,” he said.
Drafted by a large language model from the source reporting linked above, then screened by automated publishing checks. It is not read by a journalist before publication. Some articles cite our Alpha Score. Verify prices and figures against the original source. Educational coverage, not personalized advice.